Capital World Investors Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

Capital World Investors bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, HoldingsChannel reports. The fund bought 2,361,012 shares of the company’s stock, valued at approximately $73,687,000.

A number of other large investors have also modified their holdings of TEVA. Allworth Financial LP boosted its holdings in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. Grove Bank & Trust grew its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Global Retirement Partners LLC grew its stake in Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. grew its stake in Teva Pharmaceutical Industries by 1,823.2% during the 4th quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after purchasing an additional 1,495 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 3.3%

NYSE:TEVA opened at $34.35 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The business’s 50 day moving average is $33.00 and its two-hundred day moving average is $31.81. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a market cap of $39.50 billion, a PE ratio of 25.83, a P/E/G ratio of 3.39 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the transaction, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This trade represents a 64.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 421,470 shares of company stock worth $14,570,945 over the last quarter. 0.54% of the stock is owned by corporate insiders.

Analyst Ratings Changes

TEVA has been the subject of a number of recent analyst reports. UBS Group raised their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.